[1]
Zhou, B.Y.; An, C.N.; Pu, X.P. Current status of research and development of new tyrosine kinase inhibitors. Chin. New Drug J., 2011, 20(17), 1661-1666.
[2]
Arora, A.; Scholar, E.M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther., 2005, 315(3), 971-979.
[3]
Jiang, M.; Liu, D.; Lan, S.P. Progressed in quinolines as protein tyrosine kinase inhibitors. Chem. Reagents., 2013, 35(4), 333-336.
[4]
Erlichman, C.; Hidalgo, M.; Boni, J.P.; Martins, P.; Quinn, S.E.; Zacharchuk, C.; Amorusi, P.; Adjei, A.A.; Rowinsky, E.K. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol., 2006, 24(15), 2252-2260.
[5]
Wang, Y.; Long, Y.Q. Advances in small-molecule inhibitors of protein tyrosine kinases. Chin. J. Org. Chem., 2011, 31(10), 1595-1606.
[6]
Liu, B.; You, Q.D.; Li, Z.Y. Design, synthesis and anti-tumour activity of 6,7-disubstituted 4- (heteroarylamino)quinoline-3-carbonitrile derivatives. Chin. Chem. Lett., 2010, 21, 554-557.
[7]
Boschelli, D.H.; Ye, F.; Wang, Y.D.; Dutia, M.; Johnson, S.L.; Wu, B.Q.; Miller, K.; Powell, D.W.; Yaczko, D.; Young, M.; Tischler, M.; Arndt, K.; Discafani, C.; Etienne, C.; Gibbons, J.; Grod, J.; Lucas, J.; Weber, J.M.; Boschelli, F. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem., 2001, 44(23), 3965-3977.
[8]
Golas, J.M.; Arndt, K.; Etienne, C.; Lucas, J.; Nardin, D.; Gibbons, J.; Frost, P.; Ye, F.; Boschelli, D.H.; Boschelli, F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res., 2003, 63(2), 375-381.
[9]
Wissner, A.; Mansour, T.S. The development of HKI-272 and related compounds for the treatment of the cancer. Arch. Pharm. Chem. Life Sci, 2008, 341(8), 465-477.
[10]
Cao, X.; You, Q.D.; Li, Z.Y.; Guo, Q.L.; Shang, J.; Yan, M.; Chem, J.W.; Chen, M. Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase. Bioorg. Med. Chem., 2008, 16(11), 5890-5898.
[11]
Liu, B.Q.; You, Q.D.; Li, Z.Y. Synthesis and biological evaluation of 3-quinolinecarbonitrile-7-amide derivatives. Acta Pharm. Sin., 2009, 44(8), 879-884.
[12]
Liao, J.J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem., 2007, 50(3), 409-424.
[13]
Zhang, S.L.; Zhao, Y.F.; Liu, Y.J.; Chen, D.; Lan, W.H.; Zhao, Q.L.; Dong, C.C.; Xia, L.; Gong, P. Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives. Eur. J. Med. Chem., 2010, 45(8), 3504-3510.
[14]
Liu, D.; Luan, T.; Kong, J.; Zhang, Y.; Wang, H.F. Synthesis and anti-tumor activities of 4-anilino-quinoline derivatives. Molecules, 2016, 21, 21.
